Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Revenue of Oculis Holding AG (OCS)
Revenue in 2023 (TTM): $883 K
According to Oculis Holding AG's latest financial reports the company's current revenue (TTM) is $883 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Oculis Holding AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $883 K | $-28,364,000 | $-45,726,000 | $-88,695,000 | $-88,802,000 |
| 2022 | $912 K | $-21,312,000 | $-31,951,000 | $-38,643,000 | $-38,698,000 |
| 2021 | $960 K | $-8,608,000 | $-12,976,000 | $-18,524,000 | $-18,552,000 |
| 2020 | $993 K | $-8,344,000 | $-12,097,000 | $-14,790,000 | $-14,873,000 |